These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 26308893)

  • 21. Selection of metastasis competent subclones in the tumour interior.
    Zhao Y; Fu X; Lopez JI; Rowan A; Au L; Fendler A; Hazell S; Xu H; Horswell S; Shepherd STC; Spain L; Byrne F; Stamp G; O'Brien T; Nicol D; Augustine M; Chandra A; Rudman S; Toncheva A; Pickering L; Sahai E; Larkin J; Bates PA; Swanton C; Turajlic S; ; Litchfield K
    Nat Ecol Evol; 2021 Jul; 5(7):1033-1045. PubMed ID: 34002049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evolutionary hybrid cellular automaton model of solid tumour growth.
    Gerlee P; Anderson AR
    J Theor Biol; 2007 Jun; 246(4):583-603. PubMed ID: 17374383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'.
    Pisco AO; Huang S
    Br J Cancer; 2015 May; 112(11):1725-32. PubMed ID: 25965164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Game-theory models of interactions between tumour cells.
    Tomlinson IP
    Eur J Cancer; 1997 Aug; 33(9):1495-500. PubMed ID: 9337695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer.
    Mengelbier LH; Karlsson J; Lindgren D; Valind A; Lilljebjörn H; Jansson C; Bexell D; Braekeveldt N; Ameur A; Jonson T; Kultima HG; Isaksson A; Asmundsson J; Versteeg R; Rissler M; Fioretos T; Sandstedt B; Börjesson A; Backman T; Pal N; Øra I; Mayrhofer M; Gisselsson D
    Nat Commun; 2015 Jan; 6():6125. PubMed ID: 25625758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leveraging single-cell sequencing to unravel intratumour heterogeneity and tumour evolution in human cancers.
    Bowes AL; Tarabichi M; Pillay N; Van Loo P
    J Pathol; 2022 Jul; 257(4):466-478. PubMed ID: 35438189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular automata coupled with steady-state nutrient solution permit simulation of large-scale growth of tumours.
    Shrestha SM; Joldes GR; Wittek A; Miller K
    Int J Numer Method Biomed Eng; 2013 Apr; 29(4):542-59. PubMed ID: 23382053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic instability in cancer: biological and mathematical approaches.
    Komarova NL
    Cell Cycle; 2004 Aug; 3(8):1081-5. PubMed ID: 15254400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug resistance, epigenetics, and tumor cell heterogeneity.
    Hoey T
    Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inferring mutational timing and reconstructing tumour evolutionary histories.
    Turajlic S; McGranahan N; Swanton C
    Biochim Biophys Acta; 2015 Apr; 1855(2):264-75. PubMed ID: 25827356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers.
    Sinkala M; Mulder N; Patrick Martin D
    Commun Biol; 2019; 2():414. PubMed ID: 31754644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal distribution and intratumour heterogeneity of the B-cell repertoire in oesophageal squamous cell carcinoma.
    Zhang C; Huang H; Miao Y; Xiong H; Lu Z
    J Pathol; 2018 Nov; 246(3):323-330. PubMed ID: 30027584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer in light of experimental evolution.
    Sprouffske K; Merlo LM; Gerrish PJ; Maley CC; Sniegowski PD
    Curr Biol; 2012 Sep; 22(17):R762-71. PubMed ID: 22975007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay of Darwinian Selection, Lamarckian Induction and Microvesicle Transfer on Drug Resistance in Cancer.
    Álvarez-Arenas A; Podolski-Renic A; Belmonte-Beitia J; Pesic M; Calvo GF
    Sci Rep; 2019 Jun; 9(1):9332. PubMed ID: 31249353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of cell-cell interactions in a two-phase model for avascular tumour growth.
    Breward CJ; Byrne HM; Lewis CE
    J Math Biol; 2002 Aug; 45(2):125-52. PubMed ID: 12181602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
    Nijman SMB
    Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome.
    Caswell DR; Swanton C
    BMC Med; 2017 Jul; 15(1):133. PubMed ID: 28716075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer stem cells: A product of clonal evolution?
    van Niekerk G; Davids LM; Hattingh SM; Engelbrecht AM
    Int J Cancer; 2017 Mar; 140(5):993-999. PubMed ID: 27676693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The challenge of intratumour heterogeneity in precision medicine.
    Seoane J; De Mattos-Arruda L
    J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.
    van Esterik M; Van Gool IC; de Kroon CD; Nout RA; Creutzberg CL; Smit VTHBM; Bosse T; Stelloo E
    Oncotarget; 2017 Apr; 8(15):25542-25551. PubMed ID: 28424422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.